U.S. Markets close in 6 hrs 17 mins

Kymera Therapeutics, Inc. (KYMR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
59.99+0.42 (+0.71%)
As of 9:42AM EDT. Market open.

Kymera Therapeutics, Inc.

200 Arsenal Yards Boulevard
Suite 230
Watertown, MA 02472
United States
857 285 5300
http://www.kymeratx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees92

Key Executives

NameTitlePayExercisedYear Born
Dr. Bruce L. Booth Ph.D., D.Phil.Co-Founder & Chairman26.53kN/A1974
Dr. Nello Mainolfi M.D., Ph.D.Co-Founder, Pres, CEO & Director832.62kN/A1979
Dr. Richard Chesworth Ph.D.Chief Scientific Officer447.88kN/A1970
Dr. Jared A. GollobChief Medical Officer577.21kN/A1964
Mr. Bruce N. Jacobs CFAChief Financial OfficerN/AN/AN/A
Mr. Brian Albarran M.B.A., Ph.D.VP of Strategy & OperationsN/AN/AN/A
Mr. Michael J. TodiscoVP of Accounting & Fin.N/AN/A1965
Mr. Paul CoxVP of Investor Relations & CommunicationsN/AN/AN/A
Ms. Karen Martin J.D., Ph.D.VP & Head of LegalN/AN/AN/A
Ms. Paige CochranVP of HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kymera Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.